Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03657836
Other study ID # AP05135073
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2018
Est. completion date December 1, 2020

Study information

Verified date February 2021
Source Nazarbayev University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial studies the effect of sublimated mare milk supplement on gut microbiome of patients with acute bronchitis.


Description:

Food has a significant effect on the health of the body, the relationship between diet and health actualizes the importance of expanding the research of functional products. In mare's milk contains about 40 biological components necessary for the human body: amino acids, fats, enzymes (lysozyme, amylase), microelements (calcium, sodium, potassium, phosphorus, iron, magnesium, copper, iodine, sulfur, cobalt, zinc, bromine) and vitamins (A, C, B1, B2, B6, B12, E, H, PP, beta-carotene, folic acid) in optimally balanced proportions. A high percentage of nutrients, including vitamins, amino acids, contribute to immunomodulation, increasing the adaptogenic properties of the body. Valiev A demonstrated the effect of the essential fatty acids of mare's milk on immunocompetent cells and non-specific resistance after 6 weeks from the beginning of inclusion in the ration of mare's milk. Secretory IgA is the main immunoglobulin of mare's milk. The homology of human secretory IgA and mare's was previously demonstrated by cross-reactions using human anti-IgA antiserum. The mare's milk has a powerful detoxification effect, the mare's microflora neutralizes the effect of mutagens, possesses, replenishes with the necessary complex of nutrients and removes toxins from the body. The milk has a certain degree of antimicrobial effect in relation to opportunistic and pathogenic fungi, bacteria and viruses due to its own microflora. The mare's milk is rich in active substances, natural enzymes that help regulate intestinal flora, limiting the growth of unwanted bacteria and increasing the growth of bifidobacteria and lactic acid bacteria. In addition, the composition of mare's milk provided immunoglobulins A, M and G, which act as a marker of those microorganisms that can be pathogenic, which facilitates the protection task. The high antimicrobial activity of mare's milk is associated with the lysozyme contained in it, immunoglobulins, lactoperoxidase and lactoferrin. Getting into the digestive tract lysozyme has a powerful normalizing effect on the composition of the microbial flora of the mouth and intestines. Lysozyme of breast milk is 100 times more active than lysozyme of cow's milk. It not only inhibits the growth of pathogenic flora, but also promotes the growth of bifidoflora in the intestines of infants. In the framework of the project, methods for the restoration of the mucos layer of the intestine after antibiotic therapy will be developed. In order to develop the algorithm, preliminary studies will be made of changes in the structure of the intestinal microbiota after antibiotic therapy. Recruiting of patients with infectious / non-infectious pathology is supposed, clinical and laboratory examination, biomaterial sampling during antibiotic therapy, 1-5 days and 1-60 days after completion will be performed. Along with the study of microflora, local immunity studies will be carried out. To study the fundamental foundations, experimental studies will be carried out on laboratory animals. On the basis of the knowledge obtained, an algorithm for the restoration of the mucinous layer of the intestine after antibiotic therapy will be published in the form of methodological recommendations.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date December 1, 2020
Est. primary completion date January 20, 2019
Accepts healthy volunteers No
Gender All
Age group 4 Years to 5 Years
Eligibility Inclusion Criteria: - Patients of both sexes aged 4-5 years - The voluntary informed consent of the parent to participate in the study - Established diagnosis of acute upper respiratory tract disease with prescription of antibacterial therapy - The duration of symptoms of acute upper respiratory tract disease no more than 72 hours - Lack of prescription of antibacterial drugs in the last 3 months Exclusion Criteria: - Severe forms of acute infections - The presence in the history of taking probiotics and antibiotics for three months before admission to hospital - Presence in the anamnesis of chronic diseases of the digestive tract, and also of any surgeries on the digestive tract - The presence of severe concomitant diseases of the kidneys, liver, cardiovascular, respiratory and other body systems, cancer, mental and decompensated endocrine diseases, tuberculosis, HIV infection - Patient involvement in other clinical trials within the last 3 months - Lack of willingness of the patient to cooperate with the doctor-researcher

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Sublimated mare milk supplement
The dietary supplement consisting of sublimated mare milk packed in single-dose sachet.
Drug:
Standard antibiotic therapy
Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.

Locations

Country Name City State
Kazakhstan University Medical Center Astana

Sponsors (3)

Lead Sponsor Collaborator
Nazarbayev University Medical Center Eurasia Invest Ltd., Ministry of Education and Science, Republic of Kazakhstan

Country where clinical trial is conducted

Kazakhstan, 

References & Publications (9)

ADIYAR NURGAZIYEV, YERMEK AITENOV et al. Effect of mare's milk prebiotic supplementation on the gut microbiome and the immune system following antibiotic therapy // B IOD I V E R S I T A S.- Volume 21, Number 11, November 2020 Pages: 5065-5071 DOI: 10.130

Almagul Kushugulova, Samat Kozhakhmetov. Mare's milk as a prospective functional product //Functional Foods in Health and Disease. = 2018; 8(11): 537-543

Foekel C, Schubert R, Kaatz M, Schmidt I, Bauer A, Hipler UC, Vogelsang H, Rabe K, Jahreis G. Dietetic effects of oral intervention with mare's milk on the Severity Scoring of Atopic Dermatitis, on faecal microbiota and on immunological parameters in patients with atopic dermatitis. Int J Food Sci Nutr. 2009;60 Suppl 7:41-52. doi: 10.1080/09637480802249082. Epub 2009 May 21. — View Citation

Hancock JT, Salisbury V, Ovejero-Boglione MC, Cherry R, Hoare C, Eisenthal R, Harrison R. Antimicrobial properties of milk: dependence on presence of xanthine oxidase and nitrite. Antimicrob Agents Chemother. 2002 Oct;46(10):3308-10. — View Citation

Pahud JJ, Mach JP. Equine secretory IgA and secretory component. Int Arch Allergy Appl Immunol. 1972;42(2):175-86. — View Citation

Palmer AC. Nutritionally mediated programming of the developing immune system. Adv Nutr. 2011 Sep;2(5):377-95. doi: 10.3945/an.111.000570. Epub 2011 Sep 6. Review. — View Citation

SAMAT KOZHAKHMETOV, DMITRIY BABENKO. The combination of mare's milk and grape polyphenol extract for treatment of dysbiosis induced by dextran sulfate sodium // B IOD I V E R S I T A S Volume 21, Number 5, May 2020 Pages: 2275-2280 DOI: 10.13057/biodiv/d2

Valiev AG. [Features of secondary immune response and status of nonspecific resistance of the rat, fed rations with mare's milk, rich in essential fatty acids]. Vopr Pitan. 2001;70(5):10-3. Russian. — View Citation

Wulijideligen, Asahina T, Hara K, Arakawa K, Nakano H, Miyamoto T. Production of bacteriocin by Leuconostoc mesenteroides 406 isolated from Mongolian fermented mare's milk, airag. Anim Sci J. 2012 Oct;83(10):704-11. doi: 10.1111/j.1740-0929.2012.01010.x. Epub 2012 Mar 13. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in intestinal microbial composition Rectal swabs will be taken for further analysis of DNA sequence with MiSeq Reporter PCR Amplicon. Baseline, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 10, Day 15, Day 20, Day 25, Day 30, Day 35, Day 40, Day 45, Day 50, Day 55, Day 60
Primary Changes in intestinal immune status biomarkers. Levels of immune markers (cytokines, secretory Immunoglobulin A, interleukins) will be assessed from stool samples. Baseline, Day 60
Secondary Changes in weight of the patient Weight will be assessed according to percentile tables Baseline, Day 60
Secondary Defecation frequency Defecation frequency based on patient's/parent's/guardian's reports over period of 60 days Baseline, up to 60 days
Secondary Changes in consistency of stool Consistency of stool will be evaluated according to Bristol scale with severe hard lumps and liquid stool being a severe constipation (Type 1) and severe diarrhea (Type 7) respectively. Baseline, Day 60
Secondary Changes in color of stool, Stool color changes will be assessed based on baseline and final visit (Day 60). Baseline, Day 60
See also
  Status Clinical Trial Phase
Completed NCT03711292 - Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings N/A
Not yet recruiting NCT03517215 - The Development and Testing of a Scaling Strategy for a Community-Based Primary Care Antimicrobial Stewardship Program N/A
Completed NCT01420445 - Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis Phase 2
Completed NCT00360464 - A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases Phase 3
Completed NCT05344638 - A Clinical Trial to Evaluate the Safety and Efficacy of "AG1904" in Acute Bronchitis Phase 3
Completed NCT06457269 - Evaluating the Potential of Large Language Models for Respiratory Disease Consultations N/A
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT03827590 - Clinical Trials to Assess the Efficacy and Safety of HLIM Phase 3
Completed NCT02792946 - Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis Phase 3
Completed NCT01875757 - Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life Phase 3
Recruiting NCT04252963 - Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase) Phase 4
Recruiting NCT06411925 - The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients Phase 4
Completed NCT01416480 - Clinical Trial to Evaluate the Safety and Efficacy of "Theobromine Capsule" as an Antitussive in Acute Cougher Phase 3
Enrolling by invitation NCT05916768 - Management of Acute Bronchitis With Pelargonium Sidoides Extract N/A
Completed NCT03309800 - A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients Phase 2
Completed NCT02250027 - A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on) Phase 2
Not yet recruiting NCT03310385 - Efficacy and Safety of GHX02 in the Treatment of Acute Bronchitis Phase 2
Completed NCT03654196 - A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients Phase 3
Completed NCT03011515 - Evaluating a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Patients With Lower Respiratory Tract Infection (LRTI)
Completed NCT02045394 - Epidemiology and Diagnosis of Haemoptysis: a Multicenter Study N/A